Webinar: GENERIC TKIs IN CML
The Glivec patent expires in most countries latest on 21 Dec 2016.
The CML Advocates Network has been following the situation of TKI generics closely for 3 years, and has now provided a webinar which summarizes the current status.
This webinar answers some important questions, such as:
- What are generics, and do they differentiate from innovator products?
- Which generics of CML Tyrosine Kinase Inhibitors exist?
- What do we know about efficacy and safety?
- What information on CML generics is available to patients?
- What has the patient advocacy community done so far?
- What can patients and patient advocacy groups do about CML generics?
More can be found on our CML Advocates Network Knowledge Base on CML Generics at http://www.cmladvocates.net/generics.
If you want access to the slides, please contact Jan Geissler at .
Webstream via AuthorStream (allows to skip slides)
Olga Lucia Jimenez
15.12.2016 (12:20:48)
Generic drugs for cml
15.12.2016 (12:20:48)
Would like to have access to the webinar
Why drugs aren't enough: People living with CML tell it like it is
youtube.com/watch?v=PBx5nE…
@cmlnet @UHN… twitter.com/i/web/status/1…
Retweeted Monday, 18 June 2018
#EHA23 is over now, but some more real work is starting for the patient representatives. The first ever #HEMCAB i.e… twitter.com/i/web/status/1…
Retweeted Sunday, 17 June 2018
The European Hematology Association annual congress #EHA23 has finished today. More information will be available v… twitter.com/i/web/status/1…